title: [Intra-articular glucocorticoid injections in joint diseases].
abstract: Intra-articular glucocorticosteroid injections are widely used in mono- or oligoarticular flares of patients with rheumatoid arthritis and other aseptic inflammatory joint diseases, as well as in osteoarthritis. Rapid and pronounced, but usually temporary, suppression of local joint inflammation may be achieved with only minor systemic effect. In osteoarthritis the effect is brief and transient. Triamcinolone hexacetonide provides the longest clinical effect, but since this drug may cause local tissue necrosis when injected outside a synovial cavity it should be used only by experienced clinicians. The risk of glucocorticoid-induced cartilage damage is discussed. The risk is probably less than that of untreated joint inflammation. Nevertheless, it is recommended that injections into the same joint are limited, for instance to one injection every six weeks and no more than three or four in one year. Furthermore, indications and contraindications should be carefully considered prior to each injection. Intra-articular glucocorticoid therapy may be of considerable clinical value in the management of aseptic arthritis, if administered on correct indications using a correct technique.
authors.affiliation: H:S Hvidovre Hospital, reumatologisk afdeling. mo@dadlnet.dk
authors.forename: M
authors.initials: M
authors.lastname: Ostergaard
authors.forename: P
authors.initials: P
authors.lastname: Halberg
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001168:Arthritis / Q000188:drug therapy*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002358:Cartilage, Articular / Q000187:drug effects; D000075202:Contraindications; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D017408:Guidelines as Topic; D006801:Humans; D007270:Injections, Intra-Articular; D010003:Osteoarthritis / Q000188:drug therapy*; D012307:Risk Factors; D014221:Triamcinolone / Q000008:administration & dosage / Q000009:adverse effects